You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
McKinsey
Baxter
Dow
McKesson

Last Updated: April 4, 2020

32 Drugs Facing Patent Expirations and Generic Entry in 2020 - 2021

Loss of Exclusivity / End of Market Exclusivity Period dates

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "32 Drugs Facing Patent Expirations and Generic Entry in 2020 - 2021" DrugPatentWatch.com thinkBiotech, 2020 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can APTIVUS (tipranavir) generic drug versions launch?

Generic name: tipranavir
Patent Expiration / Generic Entry Opportunity April 29, 2020
Generic Entry Controlled by: Patent 5,852,195

Drug Price Trends for APTIVUS
APTIVUS is a drug marketed by Boehringer Ingelheim. There are three patents protecting this drug.

This drug has one hundred and fifty-six patent family members in thirty-one countries.

See drug price trends for APTIVUS.

The generic ingredient in APTIVUS is tipranavir. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tipranavir profile page.

When can ABLAVAR (gadofosveset trisodium) generic drug versions launch?

Generic name: gadofosveset trisodium
Patent Expiration / Generic Entry Opportunity May 04, 2020
Generic Entry Controlled by: Patent 6,676,929

ABLAVAR is a drug marketed by Lantheus Medcl. There is one patent protecting this drug.

This drug has forty-three patent family members in twenty-six countries.

The generic ingredient in ABLAVAR is gadofosveset trisodium. Additional details are available on the gadofosveset trisodium profile page.

When can FORTOVASE (saquinavir) generic drug versions launch?

Generic name: saquinavir
Patent Expiration / Generic Entry Opportunity May 16, 2020
Generic Entry Controlled by: Patent 6,352,717

FORTOVASE is a drug marketed by Hoffmann La Roche. There is one patent protecting this drug.

This drug has forty patent family members in thirty-four countries.

The generic ingredient in FORTOVASE is saquinavir. There is one drug master file entry for this API. Additional details are available on the saquinavir profile page.

When can VIVITROL (naltrexone) generic drug versions launch?

Generic name: naltrexone
Patent Expiration / Generic Entry Opportunity May 19, 2020
Generic Entry Controlled by: Patent 6,379,704

Drug Price Trends for VIVITROL
VIVITROL is a drug marketed by Alkermes. There are thirteen patents protecting this drug.

This drug has one hundred and thirteen patent family members in twenty-eight countries. There has been litigation on patents covering VIVITROL

See drug price trends for VIVITROL.

The generic ingredient in VIVITROL is naltrexone. There are nineteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the naltrexone profile page.

When can EGRIFTA (tesamorelin acetate) generic drug versions launch?

Generic name: tesamorelin acetate
Patent Expiration / Generic Entry Opportunity May 26, 2020
Generic Entry Controlled by: Patent 5,861,379

EGRIFTA is a drug marketed by Theratechnologies. There are five patents protecting this drug.

This drug has forty-four patent family members in sixteen countries.

See drug price trends for EGRIFTA.

The generic ingredient in EGRIFTA is tesamorelin acetate. One supplier is listed for this generic product. Additional details are available on the tesamorelin acetate profile page.

When can QSYMIA (phentermine hydrochloride; topiramate) generic drug versions launch?

Generic name: phentermine hydrochloride; topiramate
Patent Expiration / Generic Entry Opportunity June 14, 2020
Generic Entry Controlled by: Patent 7,674,776

Drug Price Trends for QSYMIA
QSYMIA is a drug marketed by Vivus. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-four patent family members in nineteen countries. There has been litigation on patents covering QSYMIA

See drug price trends for QSYMIA.

The generic ingredient in QSYMIA is phentermine hydrochloride; topiramate. There are seventeen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the phentermine hydrochloride; topiramate profile page.

When can DENAVIR (penciclovir) generic drug versions launch?

Generic name: penciclovir
Patent Expiration / Generic Entry Opportunity June 17, 2020
Generic Entry Controlled by: Patent 5,075,445

Drug Price Trends for DENAVIR
DENAVIR is a drug marketed by Mylan. There are two patents protecting this drug.

This drug has one hundred and five patent family members in thirty-four countries. There has been litigation on patents covering DENAVIR

See drug price trends for DENAVIR.

The generic ingredient in DENAVIR is penciclovir. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the penciclovir profile page.

When can VIMOVO (esomeprazole magnesium; naproxen) generic drug versions launch?

Generic name: esomeprazole magnesium; naproxen
Patent Expiration / Generic Entry Opportunity July 06, 2020
Generic Entry Controlled by: FDA Regulatory Exclusivity

VIMOVO is a drug marketed by Horizon. There are eleven patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has fifty-one patent family members in twenty-three countries. There has been litigation on patents covering VIMOVO

See drug price trends for VIMOVO.

The generic ingredient in VIMOVO is esomeprazole magnesium; naproxen. There are seventy-four drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the esomeprazole magnesium; naproxen profile page.

When can VYXEOS (cytarabine; daunorubicin ) generic drug versions launch?

Generic name: cytarabine; daunorubicin
Patent Expiration / Generic Entry Opportunity August 03, 2020
Generic Entry Controlled by: FDA Regulatory Exclusivity

VYXEOS is a drug marketed by Celator Pharms. There are eight patents protecting this drug.

This drug has one hundred and twenty-three patent family members in twenty-four countries. There has been litigation on patents covering VYXEOS

See drug price trends for VYXEOS.

The generic ingredient in VYXEOS is cytarabine; daunorubicin . There are fifteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cytarabine; daunorubicin profile page.

When can CIPRODEX (ciprofloxacin; dexamethasone) generic drug versions launch?

Generic name: ciprofloxacin; dexamethasone
Patent Expiration / Generic Entry Opportunity August 10, 2020
Generic Entry Controlled by: Patent 6,359,016

CIPRODEX is a drug marketed by Novartis. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has forty-three patent family members in twenty-two countries. There has been litigation on patents covering CIPRODEX

See drug price trends for CIPRODEX.

The generic ingredient in CIPRODEX is ciprofloxacin; dexamethasone. There are thirty-four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the ciprofloxacin; dexamethasone profile page.

When can BIDIL (hydralazine hydrochloride; isosorbide dinitrate) generic drug versions launch?

Generic name: hydralazine hydrochloride; isosorbide dinitrate
Patent Expiration / Generic Entry Opportunity September 08, 2020
Generic Entry Controlled by: Patent 6,465,463

BIDIL is a drug marketed by Arbor Pharms Llc. There are two patents protecting this drug.

This drug has four patent family members in four countries.

See drug price trends for BIDIL.

The generic ingredient in BIDIL is hydralazine hydrochloride; isosorbide dinitrate. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the hydralazine hydrochloride; isosorbide dinitrate profile page.

When can THALOMID (thalidomide) generic drug versions launch?

Generic name: thalidomide
Patent Expiration / Generic Entry Opportunity October 23, 2020
Generic Entry Controlled by: Patent 6,315,720

THALOMID is a drug marketed by Celgene. There are nine patents protecting this drug and three Paragraph IV challenges.

This drug has forty-seven patent family members in nineteen countries. There has been litigation on patents covering THALOMID

See drug price trends for THALOMID.

The generic ingredient in THALOMID is thalidomide. There are eleven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the thalidomide profile page.

When can ESKATA (hydrogen peroxide) generic drug versions launch?

Generic name: hydrogen peroxide
Patent Expiration / Generic Entry Opportunity December 14, 2020
Generic Entry Controlled by: FDA Regulatory Exclusivity

ESKATA is a drug marketed by Aclaris. There are four patents protecting this drug.

This drug has twenty-eight patent family members in fifteen countries.

The generic ingredient in ESKATA is hydrogen peroxide. There are fifty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the hydrogen peroxide profile page.

When can DULERA (formoterol fumarate; mometasone furoate) generic drug versions launch?

Generic name: formoterol fumarate; mometasone furoate
Patent Expiration / Generic Entry Opportunity December 20, 2020
Generic Entry Controlled by: FDA Regulatory Exclusivity

Drug Price Trends for DULERA
DULERA is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.

This drug has thirty-seven patent family members in twenty-six countries. There has been litigation on patents covering DULERA

See drug price trends for DULERA.

The generic ingredient in DULERA is formoterol fumarate; mometasone furoate. There are nineteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the formoterol fumarate; mometasone furoate profile page.

When can BRIDION (sugammadex sodium) generic drug versions launch?

Generic name: sugammadex sodium
Patent Expiration / Generic Entry Opportunity January 27, 2021
Generic Entry Controlled by: Patent RE44733

BRIDION is a drug marketed by Organon Sub Merck. There are three patents protecting this drug.

This drug has fifty-six patent family members in thirty countries. There has been litigation on patents covering BRIDION

See drug price trends for BRIDION.

The generic ingredient in BRIDION is sugammadex sodium. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the sugammadex sodium profile page.

When can FERAHEME (ferumoxytol) generic drug versions launch?

Generic name: ferumoxytol
Patent Expiration / Generic Entry Opportunity February 02, 2021
Generic Entry Controlled by: FDA Regulatory Exclusivity

FERAHEME is a drug marketed by Amag Pharms Inc. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has thirteen patent family members in ten countries. There has been litigation on patents covering FERAHEME

See drug price trends for FERAHEME.

The generic ingredient in FERAHEME is ferumoxytol. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ferumoxytol profile page.

When can FORTICAL (calcitonin salmon recombinant) generic drug versions launch?

Generic name: calcitonin salmon recombinant
Patent Expiration / Generic Entry Opportunity February 02, 2021
Generic Entry Controlled by: Patent 6,440,392

FORTICAL is a drug marketed by Upsher Smith Labs. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has seven patent family members in five countries. There has been litigation on patents covering FORTICAL

The generic ingredient in FORTICAL is calcitonin salmon recombinant. There are fourteen drug master file entries for this API. Additional details are available on the calcitonin salmon recombinant profile page.

When can CRIXIVAN (indinavir sulfate) generic drug versions launch?

Generic name: indinavir sulfate
Patent Expiration / Generic Entry Opportunity February 10, 2021
Generic Entry Controlled by: Patent 6,689,761

CRIXIVAN is a drug marketed by Merck Sharp Dohme. There is one patent protecting this drug.

This drug has forty-two patent family members in thirty-five countries. There has been litigation on patents covering CRIXIVAN

See drug price trends for CRIXIVAN.

The generic ingredient in CRIXIVAN is indinavir sulfate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the indinavir sulfate profile page.

When can CYSVIEW KIT (hexaminolevulinate hydrochloride) generic drug versions launch?

Generic name: hexaminolevulinate hydrochloride
Patent Expiration / Generic Entry Opportunity February 15, 2021
Generic Entry Controlled by: FDA Regulatory Exclusivity

CYSVIEW KIT is a drug marketed by Photocure Asa. There is one patent protecting this drug.

This drug has ten patent family members in eight countries. There has been litigation on patents covering CYSVIEW KIT

The generic ingredient in CYSVIEW KIT is hexaminolevulinate hydrochloride. One supplier is listed for this generic product. Additional details are available on the hexaminolevulinate hydrochloride profile page.

When can NORTHERA (droxidopa) generic drug versions launch?

Generic name: droxidopa
Patent Expiration / Generic Entry Opportunity February 18, 2021
Generic Entry Controlled by: FDA Regulatory Exclusivity

NORTHERA is a drug marketed by Lundbeck Na Ltd.

This drug has ten patent family members in eight countries.

See drug price trends for NORTHERA.

The generic ingredient in NORTHERA is droxidopa. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the droxidopa profile page.

When can ENJUVIA (estrogens, conjugated synthetic b) generic drug versions launch?

Generic name: estrogens, conjugated synthetic b
Patent Expiration / Generic Entry Opportunity March 08, 2021
Generic Entry Controlled by: Patent 6,660,726

ENJUVIA is a drug marketed by Aspen. There are two patents protecting this drug.

This drug has seventeen patent family members in nine countries.

The generic ingredient in ENJUVIA is estrogens, conjugated synthetic b. There are three drug master file entries for this API. Additional details are available on the estrogens, conjugated synthetic b profile page.

When can OVIDREL (choriogonadotropin alfa) generic drug versions launch?

Generic name: choriogonadotropin alfa
Patent Expiration / Generic Entry Opportunity March 16, 2021
Generic Entry Controlled by: Patent 4,840,896

Drug Price Trends for OVIDREL
OVIDREL is a drug marketed by Emd Serono. There is one patent protecting this drug.

This drug has eighteen patent family members in fourteen countries.

See drug price trends for OVIDREL.

The generic ingredient in OVIDREL is choriogonadotropin alfa. One supplier is listed for this generic product. Additional details are available on the choriogonadotropin alfa profile page.

When can DORIBAX (doripenem) generic drug versions launch?

Generic name: doripenem
Patent Expiration / Generic Entry Opportunity March 30, 2021
Generic Entry Controlled by: Patent 5,317,016

DORIBAX is a drug marketed by Shionogi Inc. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has nineteen patent family members in fifteen countries. There has been litigation on patents covering DORIBAX

See drug price trends for DORIBAX.

The generic ingredient in DORIBAX is doripenem. There are five drug master file entries for this API. Additional details are available on the doripenem profile page.

When can LIPIODOL (ethiodized oil) generic drug versions launch?

Generic name: ethiodized oil
Patent Expiration / Generic Entry Opportunity April 04, 2021
Generic Entry Controlled by: FDA Regulatory Exclusivity

LIPIODOL is a drug marketed by Guerbet.

This drug has nineteen patent family members in fifteen countries.

See drug price trends for LIPIODOL.

The generic ingredient in LIPIODOL is ethiodized oil. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ethiodized oil profile page.

When can EXPAREL (bupivacaine) generic drug versions launch?

Generic name: bupivacaine
Patent Expiration / Generic Entry Opportunity April 06, 2021
Generic Entry Controlled by: FDA Regulatory Exclusivity

EXPAREL is a drug marketed by Pacira Pharms Inc. There is one patent protecting this drug.

This drug has nineteen patent family members in nine countries.

See drug price trends for EXPAREL.

The generic ingredient in EXPAREL is bupivacaine. There are twelve drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupivacaine profile page.

When can ERAXIS (anidulafungin) generic drug versions launch?

Generic name: anidulafungin
Patent Expiration / Generic Entry Opportunity April 12, 2021
Generic Entry Controlled by: Patent 5,965,525

ERAXIS is a drug marketed by Vicuron. There are three patents protecting this drug.

This drug has sixty-seven patent family members in twenty-nine countries.

See drug price trends for ERAXIS.

The generic ingredient in ERAXIS is anidulafungin. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the anidulafungin profile page.

When can OPTISON (albumin human) generic drug versions launch?

Generic name: albumin human
Patent Expiration / Generic Entry Opportunity April 20, 2021
Generic Entry Controlled by: Patent 6,723,303

OPTISON is a drug marketed by Ge Healthcare. There is one patent protecting this drug.

This drug has forty patent family members in twenty-seven countries.

See drug price trends for OPTISON.

The generic ingredient in OPTISON is albumin human. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the albumin human profile page.

When can BRIVIACT (brivaracetam) generic drug versions launch?

Generic name: brivaracetam
Patent Expiration / Generic Entry Opportunity May 12, 2021
Generic Entry Controlled by: FDA Regulatory Exclusivity

Drug Price Trends for BRIVIACT
BRIVIACT is a drug marketed by Ucb Inc. There are three patents protecting this drug.

This drug has one hundred and forty-six patent family members in forty-two countries.

See drug price trends for BRIVIACT.

The generic ingredient in BRIVIACT is brivaracetam. One supplier is listed for this generic product. Additional details are available on the brivaracetam profile page.

When can FIRMAGON (degarelix acetate) generic drug versions launch?

Generic name: degarelix acetate
Patent Expiration / Generic Entry Opportunity May 18, 2021
Generic Entry Controlled by: Patent 5,925,730

FIRMAGON is a drug marketed by Ferring. There are three patents protecting this drug.

This drug has one hundred and thirty-six patent family members in thirty-six countries. There has been litigation on patents covering FIRMAGON

See drug price trends for FIRMAGON.

The generic ingredient in FIRMAGON is degarelix acetate. One supplier is listed for this generic product. Additional details are available on the degarelix acetate profile page.

When can CONSENSI (amlodipine besylate; celecoxib) generic drug versions launch?

Generic name: amlodipine besylate; celecoxib
Patent Expiration / Generic Entry Opportunity May 31, 2021
Generic Entry Controlled by: FDA Regulatory Exclusivity

CONSENSI is a drug marketed by Coeptis. There are two patents protecting this drug.

This drug has eight patent family members in six countries.

The generic ingredient in CONSENSI is amlodipine besylate; celecoxib. There are fifty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the amlodipine besylate; celecoxib profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
McKesson
Mallinckrodt
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.